Morningstar Analysts Comment on ARM, AstraZeneca, BP

Catch up on the latest Morningstar research on UK-listed companies

Holly Cook 26 March, 2013 | 6:49PM
Facebook Twitter LinkedIn

Several of the UK's largest and best known companies have been in the headlines in the past week. Morningstar analysts provide their reactions to some of the latest news from LSE-listed multinationals.

ARM Holdings (ARM)

Following news that CEO Warren East will retire on July 1, Morningstar is maintaining its fair value estimate and moat and stewardship ratings. Simon Segars, a board member since 2005 and president of ARM will take over the CEO position. "ARM was in capable hands under East, as the company is in the midst of tremendous revenue growth as the firm's low-power processors are ideally suited to run the substantial majority of the world’s smartphones today," commented Morningstar analyst Brian Colello.

AstraZeneca (AZN)

At its investor day last week, AstraZeneca announced new strategic initiatives, including cost cutting and increasing its focus on high-reward therapeutic areas. Based on the new initiatives, Morningstar analysts don't plan to change their fair value estimate, which represents a slight premium to the current stock price. "We believe Astra's fundamental outlook remains challenged by an industry-leading amount of patent losses combined with a poor pipeline," commented Morningstar's Damien Conover. "However, from a valuation perspective, we believe the market may be slightly overestimating these problems." Conover continues to view AstraZeneca's economic moat as wide, as the company still maintains a strong portfolio of very high-margin drugs, but the lacking pipeline productivity relative to the patent losses keeps his economic moat trend rating at negative.

BP (BP.)

BP announced an $8 billion share buyback programme with the proceeds it received from divesting TNK-BP. This is roughly $3 billion more than Morningstar analysts were expecting based on management's previous comments on the subject.

Morningstar's Stephen Simko suspects the positive reaction to the news was in large part because it hints that the increasing cost estimates from Macondo-related business claims won't undo BP's previously stated plans to return a lot of cash to shareholders in the coming years via repurchases and increased dividends. 

Simko's fair value estimate for BP remains unchanged.

 

See all the latest Stock Research from Morningstar analysts here.

Not a Premium member? Find out more about Premium here.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC10,428.00 GBX3.64Rating
BP PLC390.70 GBX0.54Rating

About Author

Holly Cook

Holly Cook  is Manager, Morningstar EMEA Websites

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures